Decades of Research Leads to Promising Clinical Trial for Early Alzheimer’s Treatment

Dr. Gary Gibson, Director of the Laboratory for Mitochondrial Biology and Metabolic Dysfunction in Neurodegeneration at the Burke Neurological Institute, has dedicated his career to advancing Alzheimer’s disease research. His decades-long efforts have been pivotal in the development of a new clinical trial targeting early-stage Alzheimer’s treatment.

Read more about Dr. Gibson’s groundbreaking contributions and the clinical trial in the full article from Weill Cornell Medicine: Decades of Work Leads to Clinical Trial for Early Alzheimer’s Treatment.

Featured Researchers and Members

Gary E. Gibson, Ph.D.

Lab Director

Laboratory for Mitochondrial Biology and Metabolic Dysfunction in Neurodegeneration

Professor

Weill Cornell Medicine